September 21, 2021
25 min listen
Save
AGTC: The New Leader in Ocular Gene Therapy with Sue Washer
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this episode, Sue Washer, BS, MBA, discusses gene therapy in ophthalmology, AGTC’s clinical trial progress, as well as current and future challenges faced by both the cell therapy industry and ophthalmology.
- Welcome to another exciting episode of Eye Care insider :13
- About Washer 1:51
- Can you discuss what is gene therapy? How does it work on a basic level? 4:53
- How do companies like AGTC make gene therapy work for diseases that may not affect as many people but still make it financially successful for investors? 7:11
- Could you talk about where you are in the X-Linked Retinitis Pigmentosa candidate trials? 11:08
- Is there an estimated timeline that you have for initial data read out? 14:56
- You have another candidate for achromatopsia … I was reading you had some new data released. Could you go into more details about that? 16:23
- What do you think is the most important topic or challenge you see facing the gene therapy industry and ophthalmology today and in the future? 20:56
- Thank you so much for your insight into this fascinating topic 23:22
- How to find out more about AGTC 23:31
- Thank you for listening 24:15
Sue Washer, BS, MBA is the president and chief executive officer of AGTC.
We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. You can contact AGTC through the company’s website at www.atgc.com.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Washer is the president and CEO of AGTC.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
